PURPOSE: To evaluate clinical features of patients who underwent surgical treatment for diverticular disease of the colon. METHODS: We retrospectively reviewed the hospital records of 27 patients who were surgically treated for diverticular disease of colon at the Seoul National University Hospital from July 1993 to September 1999. We also compared our data with that of previous study of 24 patients surgically treated for the same disease from March 1982 to June 1993. RESULTS: Although the changes in the distribution of age and sex are not remarkable, increment of total number of left side colonic diverticular disease was noted (from 3 cases among 24 cases in previous study to 11 cases among 27 cases in this study). In contrast to all of right side diverticulitis were classified to stage I or II, half of left side diseases were advanced to stage III or IV by Hinchey's severity classification. Patients with right side diverticular disease were treated with surgical resection of diseased colon with low postoperative morbidity. On the other hand, patients with left side diverticular disease were treated with variety of surgical modalities from drainage alone to staged operation and there were relatively high postoperative complications including 3 cases of reoperation due to peritonitis, and one case of reoperation due to recurred diverticular disease. CONCLUSIONS: Recent increment in surgical treatment for left side diverticular disease of the colon was noted. Operations for left side colonic diverticular disease, associated with relatively advanced disease stage, exhibited high emergency operation rate and complications.
Classification ; Colon* ; Diverticulitis ; Drainage ; Emergencies ; Hand ; Hospital Records ; Humans ; Peritonitis ; Postoperative Complications ; Reoperation ; Retrospective Studies ; Seoul

PURPOSE: We wanted to evaluate the efficacy and toxicity of the newly developed oral glyceryl monooleate (GMO)-paclitaxel in a hormone refractory prostate cancer model. MATERIALS AND METHODS: A paclitaxel formulation was prepared from GMO, tricaprylin, Tween(R) 80 and paclitaxel. The tumor cells of prostate cancer (DU-145 cells) were incubated and then put into different paclitaxel concentrations. The tumoricidal activity was measured by using an indirect methylthiazol-2-yl-2,5-diphenyl tetrazolium bromide (MTT) assay. Cells of the DU-145 cell line were subcutaneously heterotransplanted into 18 nude mice, and they developed prostate cancer. The 18 mice were divided into 3 groups; the control group was injected with the DU-145 cell line (n=6), the GMO group was injected with GMO after the DU-145 cells were injected (n=6), and the oral GMO-paclitaxel group was injected with oral GMO-paclitaxel after the DU-145 cells were injected (n=6). The tumor volume was measured every week and the main organs were evaluated pathologically to determine the toxicity. RESULTS: On the MTT assay, the control group and the GMO group did not display cytotoxicity. However, treatment with the various GMO-paclitaxel formulations (0.1 microgram/ml, 1 microgram/ml, 10 microgram/ml) for treating the DU-145 cell line cancer induced cytotoxicity in a dose dependent fashion. The tumor volumes were not significantly changed in the group that was administered oral GMO-paclitaxel. However, there were significantly increased tumor volumes in the control group and the GMO group (p<0.05). Toxic changes were not detected in liver and kidney, and there was normal cellularity with a normal myeloid:erythroid ratio in the mice after the administration of oral GMO-paclitaxel. CONCLUSIONS: The newly developed oral GMO-paclitaxel has a remarkable cytotoxic effect against DU-145 cells without systemic toxicity. Therefore, oral GMO-paclitaxel therapy promises to be a safe and effective modality for treating hormone refractory prostate cancer, and it can possibly replace IV paclitaxel.
Animals ; Cell Line ; Kidney ; Liver ; Mice ; Mice, Nude ; Paclitaxel ; Prostate* ; Prostatic Neoplasms* ; Tumor Burden